Clinical trial
An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients With Severe Community-Acquired Pneumonia.
NCT05962606 is registered in ClinicalTrials.gov with Aptarion Biotech AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients With Severe Community-Acquired Pneumonia.
- Lead sponsor
- Aptarion Biotech AG
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 2, 2024
- Completion date
- March 16, 2026
- Enrollment
- 150 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.